trans-(3-hydroxy-cyclopentyl)-acetic acid methyl ester

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: trans-(3-hydroxy-cyclopentyl)-acetic acid methyl ester
• 英文别名: methyl 2-(3-hydroxycyclopentyl)acetate
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: JKYJDPCEVAGWBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  trans-(3-hydroxy-cyclopentyl)-acetic acid methyl ester 在 氯化亚砜 作用下， 生成 3-chlorocyclopentylacetic acid methyl ester
  参考文献：
  名称：

  Rǎzus, Alexandru C.; Nae, Ştefania; Stanciu, Cornel, Revue Roumaine de Chimie, 2000, vol. 45, # 7-8, p. 801 - 807

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氧代-环戊烷乙酸 在 镍 氢气 作用下， 生成 trans-(3-hydroxy-cyclopentyl)-acetic acid methyl ester
  参考文献：
  名称：

  Rǎzus, Alexandru C.; Nae, Ştefania; Stanciu, Cornel, Revue Roumaine de Chimie, 2000, vol. 45, # 7-8, p. 801 - 807

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF<br/>[FR] PIPÉRIDINES SUBSTITUÉES QUI ACCROISSENT L'ACTIVITÉ DE P53, ET UTILISATIONS DE CES COMPOSÉS
  申请人：SCHERING CORP

  公开号：WO2011046771A1

  公开（公告）日：2011-04-21

  The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

  本发明提供了如下所述的化合物的化学式（1）或其药学上可接受的盐、溶剂合物或酯。这些化合物可用作HDM2蛋白的抑制剂。还公开了包含上述化合物的药物组合物以及使用它们治疗癌症的方法。
• BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS
  申请人：Gobbi Luca

  公开号：US20090042943A1

  公开（公告）日：2009-02-12

  The present invention relates to compounds of formula (I) wherein R 1 and A are as defined in the specification as dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors, their manufacture, pharmaceutical compositions containing them and their use as medicaments. Compounds of general formula (I) have high affinity for the dopamine D 3 and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT 2A receptors and are effective in the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment.

  本发明涉及以下式（I）的化合物 其中R 1 和A如说明书中定义的作为血清素5-HT 2a 和多巴胺D 3 受体的双调节剂，它们的制备，含有它们的药物组合物以及它们作为药物的用途。一般式（I）的化合物对多巴胺D 3 和血清素（5-羟色胺；5-HT）5-HT 2A 受体具有高亲和力，并且在治疗精神分裂症等疾病以及抑郁症、焦虑症、药物依赖、痴呆症和记忆障碍等其他疾病中具有有效性。
• D3 AND 5-HT2A RECEPTOR MODULATORS
  申请人：Gobbi Luca

  公开号：US20100075983A1

  公开（公告）日：2010-03-25

  The present invention provides compounds of the general formula (I) wherein X, n and R 1 are as described herein, as well as pharmaceutically acceptable salts and esters thereof, methods for their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors, useful in the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

  本发明提供了一般式(I)的化合物，其中X、n和R1如本文所述，以及其药学上可接受的盐和酯，其制备方法，含有它们的药物组合物以及它们作为药物的用途。本发明的活性化合物是血清素5-HT2a和多巴胺D3受体的双调节剂，在认知障碍、药物成瘾、抑郁症、焦虑症、药物依赖、痴呆症、记忆障碍、包括精神分裂症、情感性精神障碍、双相情感障碍、躁狂症、精神抑郁症以及偏执狂和妄想的精神病等的治疗和/或预防中有用。
• SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT
  申请人：NOVIRA THERAPEUTICS, INC.

  公开号：US20160151375A1

  公开（公告）日：2016-06-02

  The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

  本发明涉及一种抑制、抑制或预防HBV感染的方法，包括向需要的个体施用本发明中至少一种化合物的治疗有效量。
• DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS
  申请人：Gobbi Luca

  公开号：US20090029977A1

  公开（公告）日：2009-01-29

  The present invention relates to compounds of the formula (I) wherein R 1 , R 2 , X and n are as defined in the specification as dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors, their manufacture, pharmaceutical compositions containing them and their use for the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment.

  本发明涉及公式（I）中R1、R2、X和n的化合物，其在说明书中被定义为5-HT2a和D3受体的双调节剂，它们的制备、含有它们的药物组合物以及它们用于治疗精神病性障碍以及其他疾病，如抑郁症、焦虑症、药物依赖、痴呆症和记忆障碍。